Immunic Inc (IMUX)

$1.10 -0.06 (-5.17%)
Market Cap 143.51M
Revenue (ttm) 0.00
Net Income (ttm) -97.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,024,300
Avg Vol 3,861,416
Day's Range N/A - N/A
Shares Out 130.47M
Stochastic %K 7%
Beta 1.46
Analysts Strong Sell
Price Target $4.98

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 255 9818
Website: imux.com
Address:
1200 Avenue of the Americas, Suite 200, New York, United States
Bruckner1234
Bruckner1234 Mar. 20 at 7:30 PM
$IMUX everything way down. Iraq force majeure, etc.
0 · Reply
algo888
algo888 Mar. 20 at 1:18 PM
$HCWB pesky trading action reminded me of $IMUX when it bottomed out from .70 took a week of consolidation until it broke above 1.00 again and eventually running to 1.57
2 · Reply
Stock_AHA
Stock_AHA Mar. 20 at 12:42 PM
$IMUX https://finance.yahoo.com/sectors/healthcare/articles/immunic-inc-imux-announces-european-115903318.html
0 · Reply
takingstock73
takingstock73 Mar. 20 at 11:21 AM
$IMUX I actually think this has been holding up quite well considering the market volatility to the downside
1 · Reply
coujatrader
coujatrader Mar. 20 at 8:40 AM
$IMUX train wreck lol
0 · Reply
Jw242
Jw242 Mar. 19 at 4:43 PM
$IMUX orange man can suck a big D and keel over
0 · Reply
Bruckner1234
Bruckner1234 Mar. 19 at 4:40 PM
$IMUX taken a position here today.
0 · Reply
Mvvh1987
Mvvh1987 Mar. 19 at 1:25 PM
$IMUX Stifel CNS Forum highlights Management reiterated 2026 as a transformative year ENSURE‑1 and ENSURE‑2 Phase 3 RMS readout expected end of 2026 NDA preparation already underway Vidofludimus calcium positioned as differentiated oral MS therapy Selective DHODH inhibitor without kinase off‑target effects seen with Aubagio Clean safety profile so far liver enzymes comparable to placebo Short half life and fast washout vs teriflunomide Unique dual mechanism Anti inflammatory via DHODH Neuroprotection via strong Nurr1 activation Phase 2 EMPhASIS showed low disability progression and dose dependent NfL reduction CALLIPER showed meaningful CDP reduction in PPMS Focus not just on relapses but disability and PIRA Targeting oral segment and patients sequencing off anti CD20s PPMS Phase 3 planned H2
2 · Reply
op211
op211 Mar. 19 at 8:53 AM
$VCIG bought in just because of this buy over here Was the same with $IMUX and it ran after some time from $0.6 to $1.5
0 · Reply
coujatrader
coujatrader Mar. 19 at 12:44 AM
$IMUX going on with this I’ve been here too long lol
0 · Reply
Latest News on IMUX
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Mar 10, 2026, 6:30 AM EDT - 11 days ago

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Immunic to Participate in Investor Conferences in March

Mar 3, 2026, 6:30 AM EST - 18 days ago

Immunic to Participate in Investor Conferences in March

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Feb 26, 2026, 6:30 AM EST - 23 days ago

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Immunic Announces Closing of Oversubscribed Private Placement Financing

Feb 17, 2026, 4:05 PM EST - 4 weeks ago

Immunic Announces Closing of Oversubscribed Private Placement Financing

Immunic Stock Jumps After Pricing $400 Million Private Placement

Feb 13, 2026, 11:25 AM EST - 5 weeks ago

Immunic Stock Jumps After Pricing $400 Million Private Placement

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Feb 13, 2026, 6:30 AM EST - 5 weeks ago

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Feb 4, 2026, 6:30 AM EST - 6 weeks ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Jan 7, 2026, 6:30 AM EST - 2 months ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 26, 2025, 6:30 AM EST - 4 months ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:30 AM EST - 4 months ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Immunic to Participate in Industry and Investor Conferences in November

Oct 29, 2025, 6:30 AM EDT - 5 months ago

Immunic to Participate in Industry and Investor Conferences in November

Immunic to Participate in Scientific and Investor Conferences in October

Oct 1, 2025, 6:30 AM EDT - 6 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 25, 2025, 6:30 AM EDT - 6 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 6 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Immunic to Participate in Investor and Scientific Conferences in September

Sep 4, 2025, 6:30 AM EDT - 7 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:30 AM EDT - 8 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 24, 2025, 6:30 AM EDT - 9 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 9, 2025, 5:51 PM EDT - 10 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 5, 2025, 6:30 AM EDT - 10 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 3, 2025, 4:01 PM EDT - 10 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Jun 2, 2025, 6:30 AM EDT - 10 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29, 2025, 7:05 AM EDT - 10 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. Announces Proposed Public Offering

May 28, 2025, 4:02 PM EDT - 10 months ago

Immunic, Inc. Announces Proposed Public Offering

Immunic to Participate in Scientific and Industry Conferences in May

May 2, 2025, 6:30 AM EDT - 11 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 30, 2025, 7:30 AM EDT - 11 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 28, 2025, 2:09 AM EDT - 11 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 10, 2025, 1:00 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Apr 1, 2025, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Immunic to Participate in Scientific and Investor Conferences in March

Mar 3, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Scientific and Investor Conferences in March

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 26, 2025, 6:30 AM EST - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 20, 2025, 7:30 AM EST - 1 year ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic to Participate in Investor and Scientific Conferences in February

Feb 4, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in February

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Immunic, Inc. to Participate in Investor Conference in December

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 8:37 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Immunic to Participate in Industry and Scientific Conferences in June

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

Bruckner1234
Bruckner1234 Mar. 20 at 7:30 PM
$IMUX everything way down. Iraq force majeure, etc.
0 · Reply
algo888
algo888 Mar. 20 at 1:18 PM
$HCWB pesky trading action reminded me of $IMUX when it bottomed out from .70 took a week of consolidation until it broke above 1.00 again and eventually running to 1.57
2 · Reply
Stock_AHA
Stock_AHA Mar. 20 at 12:42 PM
$IMUX https://finance.yahoo.com/sectors/healthcare/articles/immunic-inc-imux-announces-european-115903318.html
0 · Reply
takingstock73
takingstock73 Mar. 20 at 11:21 AM
$IMUX I actually think this has been holding up quite well considering the market volatility to the downside
1 · Reply
coujatrader
coujatrader Mar. 20 at 8:40 AM
$IMUX train wreck lol
0 · Reply
Jw242
Jw242 Mar. 19 at 4:43 PM
$IMUX orange man can suck a big D and keel over
0 · Reply
Bruckner1234
Bruckner1234 Mar. 19 at 4:40 PM
$IMUX taken a position here today.
0 · Reply
Mvvh1987
Mvvh1987 Mar. 19 at 1:25 PM
$IMUX Stifel CNS Forum highlights Management reiterated 2026 as a transformative year ENSURE‑1 and ENSURE‑2 Phase 3 RMS readout expected end of 2026 NDA preparation already underway Vidofludimus calcium positioned as differentiated oral MS therapy Selective DHODH inhibitor without kinase off‑target effects seen with Aubagio Clean safety profile so far liver enzymes comparable to placebo Short half life and fast washout vs teriflunomide Unique dual mechanism Anti inflammatory via DHODH Neuroprotection via strong Nurr1 activation Phase 2 EMPhASIS showed low disability progression and dose dependent NfL reduction CALLIPER showed meaningful CDP reduction in PPMS Focus not just on relapses but disability and PIRA Targeting oral segment and patients sequencing off anti CD20s PPMS Phase 3 planned H2
2 · Reply
op211
op211 Mar. 19 at 8:53 AM
$VCIG bought in just because of this buy over here Was the same with $IMUX and it ran after some time from $0.6 to $1.5
0 · Reply
coujatrader
coujatrader Mar. 19 at 12:44 AM
$IMUX going on with this I’ve been here too long lol
0 · Reply
SwingTradezzz
SwingTradezzz Mar. 18 at 5:39 PM
$IMUX
0 · Reply
Stock_AHA
Stock_AHA Mar. 18 at 3:45 PM
$IMUX https://finance.yahoo.com/news/immunic-details-vidofludimus-calcium-ms-141304867.html
0 · Reply
algo888
algo888 Mar. 18 at 12:49 PM
$HCWB price action reminded me of $IMUX Going all in from .72 topping out @ 1.50
0 · Reply
Jack8alot
Jack8alot Mar. 17 at 10:47 PM
$IMUX Its about time we get Scooped up for $$$$$$$$$$
0 · Reply
Cattitude
Cattitude Mar. 17 at 9:36 PM
$IMUX 🤔
0 · Reply
SwingTradezzz
SwingTradezzz Mar. 17 at 9:29 PM
$IMUX $IBRX DONT SLEEP ON THESE
1 · Reply
Jw242
Jw242 Mar. 17 at 9:10 PM
$IMUX shorty covering
4 · Reply
Bronzeback
Bronzeback Mar. 17 at 7:14 PM
$IMUX No worries on the RS of and when it happens, the science behind this is immeasurable. Between this company and $OCGN , there is more to see besides charts, trends, shorters, and memes. Enjoy the ride and St Pat’s Day
0 · Reply
JPietersen
JPietersen Mar. 17 at 7:05 PM
$IMUX Of course there will be an RS. They don't have enough shares remaining in the float to satisfy all those warrants when they decided to give away the company for 87 cents/share. They need to RS down the overall float and then issue another 458M shares to satisfy the warrants.
0 · Reply
SwingTradezzz
SwingTradezzz Mar. 17 at 4:52 PM
$IBRX $IMUX 2 SAFE BIOTECH STOCKS TO INVEST WITH UPSIDE VERY SOON. $IMUX A VERY STEADY CONSISTENT CLIMB. $IBRX A VERY VOLATILE BUT READY TO LAUNCH CLIMB
0 · Reply
smar312
smar312 Mar. 17 at 3:39 PM
$IMUX An announcement that Imux has regained compliance should be forthcoming and will probably give stock price a bump.
0 · Reply
Share54321
Share54321 Mar. 17 at 2:49 PM
$IMUX My prognosis: No RS after vote in April as IMUX is NASDAQ compliant again. RS is normally an emergency measure to stay compliant. Not needed for some time and never if IMUX stays over 1 $. I do expect a test of the 1 $ line in the coming days or weeks though. Maybe a nice drop after vote for RS. But after that I expect IMUX to target 2 $ and more as we get closer to big data and possible FDA application afterwards… All personal opinion. I stay in and will buy more when hitting 1 $ or less.
2 · Reply